Persistent opacification of the left ventricle and myocardium with a new echo contrast agent.

Echo contrast agents with long survival times open up new fields of application in the investigation of tissue perfusion and cardiovascular function. The purpose of this study was to characterize the time-course of the opacification of the heart cavities and myocardium with a new long-lasting second-generation, phospholipid-based echo contrast agent containing perfluoropentane (BY963-C5F12), and to compare its contrast potency with that of air-filled phospholipid monolayer (BY963-air). Doses of 0.03 mL/kg, 0.08 mL/kg and 0.16 mL/kg of BY963-air and BY963-C5F12 were administered intravenously to six conscious dogs weighing 25-36 kg. A transthoracic echocardiography was performed to evaluate peak intensity and area under the curve (AUC) from regions-of-interest placed in the right ventricle, left ventricle and left ventricular (LV) myocardium using acoustic densitometry. All injections were well tolerated, without wall-motion abnormalities or ECG changes. The LV cavity and myocardium were uniformly and well opacified for both echo contrast agents. However, at all administered doses, the contrast efficacy and duration were much more pronounced using BY963-C5F12 than with BY963-air. For the myocardium, the average peak intensity increased from 11.9+/-2.8 to 15.0+/-2.7 (not significant) following injection of BY963-air and from 12.8+/-3.2 to 18.7+/-2.8 (p < 0.01) following IV administration of BY963-C5F12; the latter corresponding to an increase in myocardial opacification of 46%. In conclusion, these results show the high myocardial opacification of BY963-C5F12 as compared to BY963-air. The simple incorporation of a perfluorocarbon gas into the phopholipid monolayer BY963 instead of air alters the acoustic properties of this contrast agent, resulting in qualitatively different application potentials for tissue opacification.